[1] |
JIANG Haitao, XU Yangxian .
Research progress on the resistance mechanism of anti-angiogenesis targeted drugs in the treatment of colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 193-199.
|
[2] |
ZHAO Quanming, YANG Mandou, HU Yibo, SU Youtong, PU Li, ZHANG Yu, LI Wenliang.
Research progress on drug treatment and drug resistance mechanism of gastrointestinal stromal tumors
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 82-89.
|
[3] |
WU Tingkai, REN Chongchong, ZHANG Wanwan, LIU Bei.
Research progress of FLT3 inhibitors and drug resistance mechanisms in acute myeloid leukemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 90-98.
|
[4] |
LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing.
Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
|
[5] |
LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing.
Functions of CRABP2 in tumorigenesis and progression
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
|
[6] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[7] |
WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei.
Research progress on pathogenic fusion gene in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
|
[8] |
DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli.
Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
|
[9] |
MENG Qiang, LIU Kexin.
Research status and prospect of transporter-mediated drug-drug interactions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
|
[10] |
YANG Hechun, SHI Daohua .
Research progress of small molecule inhibitors that reverse tumor drug resistance by regulating tumor glucose metabolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 836-840.
|
[11] |
HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan.
Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
|
[12] |
WEI Songchang, YANG Hongqi, ZHANG Hongjuan, SHI Xiaoli, REN Kaiwen.
Correlation between the expression of RON protein and CXC chemokine receptor 4 protein and abiraterone resistance in patients with castration-resistant prostate cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 414-422.
|
[13] |
JIN Le, JIANG Duochen, CHEN Hongxiao, LIU Su, CHEN Zhaolin, JU Jing.
Quercetin reverses adriamycin resistance by activating GSK-3β/β-catenin pathways through GAS5 in breast cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1344-1351.
|
[14] |
WANG Ziyuan, SUN Mingyu.
Advances in research on long non-coding RNA in drug resistance of colorectal cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 796-802.
|
[15] |
YANG Yanlang, LI Yan, WANG Lin.
Distribution and drug resistance of bacterial pathogens in the infecting inpatients of department of nephrology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 203-208.
|